What Dissolves Plaque in Arteries?

No pill or supplement literally dissolves arterial plaque the way a solvent dissolves grease. What the body can do, with the right pharmaceutical help, is slowly shrink plaques and remodel them into more stable structures less likely to rupture and cause a heart attack. Statins are the best-studied tool for this, and combining them with newer drugs can push the effect further. The picture gets more interesting when you factor in anti-inflammatory medications, lifestyle changes, and a handful of supplements with preliminary but intriguing evidence.

How Plaque Builds Up in the First Place

Arterial plaque is not a simple clog sitting inside a pipe. It starts when cholesterol-carrying particles, especially oxidized LDL, slip beneath the inner lining of an artery wall. White blood cells rush to the scene and try to clean up the cholesterol by swallowing it. When they gorge themselves on too much oxidized LDL, they become bloated “foam cells” that get stuck in the artery wall rather than leaving with their cargo.¹ These foam cells are a driving force in plaque formation and growth.²

Over time, layers of foam cells, dead cell debris, calcium deposits, and fibrous tissue accumulate into a plaque. Not all foam cells come from white blood cells: smooth muscle cells in the vessel wall also transform into foam cells, making up roughly half of them in human plaques.³ This means plaque is deeply embedded in the artery wall itself, which is why you cannot simply flush it away. Any meaningful reversal requires coaxing the body’s own transport systems to pull cholesterol back out of those cells and carry it to the liver for disposal, a process researchers call reverse cholesterol transport.⁴

Statins Are Still the Main Event

Statins lower LDL cholesterol by blocking the liver enzyme that makes it. That much is well known. What gets less attention is that statins can actually shrink existing plaques, not just slow their growth. A pooled analysis of trials using intravascular ultrasound to measure plaque volume directly found that statin-treated patients had measurably smaller plaques compared to those on placebo.⁵ The shrinkage is real but modest: we are talking about small reductions in total plaque volume, not dramatic clearing of arteries. Still, even modest regression matters because it often comes with a shift in plaque composition from soft, rupture-prone tissue toward denser, more stable structures.

The degree of regression depends heavily on how low LDL gets. When trials push LDL below roughly 70 mg/dL with high-intensity statins, plaque regression is more consistent. Above that threshold, statins tend to slow progression without actually reversing it. This dose-response relationship is why cardiologists push for aggressive LDL lowering in people who already have coronary artery disease.

Adding a Second Drug to Statins

For patients who don’t reach low enough LDL on a statin alone, two add-on classes have strong evidence for further plaque reduction.

Ezetimibe

Ezetimibe blocks cholesterol absorption in the gut and pairs well with statins because the two drugs work through completely different mechanisms. Meta-analyses comparing the combination to statins alone consistently show extra plaque shrinkage. One pooled analysis found the combination reduced total plaque volume significantly more than a statin by itself.⁶ A separate meta-analysis in patients with acute coronary syndrome confirmed that adding ezetimibe to a statin was significantly more effective at reducing coronary plaque than a statin alone.⁷ Ezetimibe is generic, inexpensive, and well tolerated, which makes it one of the most practical additions to statin therapy.

PCSK9 Inhibitors

PCSK9 inhibitors are injectable drugs that can slash LDL by an additional 50 to 60 percent on top of what a statin achieves. Combining a PCSK9 inhibitor with a statin drives LDL to very low levels and produces the most dramatic plaque changes seen in clinical trials. In one study, patients on both alirocumab and atorvastatin saw their LDL drop from about 3.6 to 1.5 mmol/L, with significantly greater increases in the artery’s open space and greater reductions in plaque volume compared to either drug alone.⁸ A meta-analysis of combination therapy also found that PCSK9 inhibitors thickened the fibrous cap covering the plaque, which is a marker of plaque stability.⁹ A thicker cap means the plaque is less likely to crack open and trigger a clot.

PCSK9 inhibitors are expensive and require injections every two to four weeks. They tend to be reserved for people at very high cardiovascular risk or those who cannot tolerate statins at adequate doses. But for plaque regression specifically, the combination of a statin plus a PCSK9 inhibitor is the most potent option available today.

Why Shrinking Plaque Is Not the Whole Story

Cardiologists care less about whether a plaque is big and more about whether it is dangerous. A large, stable plaque with a thick fibrous cap and mostly calcified interior can sit quietly for decades. A small plaque with a thin cap and a pool of soft, fatty material underneath can rupture without warning, spilling its contents into the bloodstream and triggering a clot that blocks the artery. That is how most heart attacks happen.

The real benefit of aggressive lipid lowering may be less about shrinking plaque volume and more about transforming plaque composition. Statins and PCSK9 inhibitors shift plaques from soft and vulnerable to dense and stable. This stabilization effect likely explains why these drugs reduce heart attacks and strokes by a greater proportion than you would predict from the plaque-volume changes alone.

Targeting Inflammation Directly

Even among patients who bring their LDL to rock-bottom levels on statins, a stubborn residual risk of heart attacks remains. Researchers have increasingly pointed to chronic inflammation in the artery wall as a major contributor. Among people already taking statins, the level of a blood marker for inflammation called high-sensitivity C-reactive protein is actually a stronger predictor of cardiovascular death than LDL cholesterol itself.¹⁰

Colchicine, an old and inexpensive anti-inflammatory drug originally used for gout, has emerged as a surprisingly effective tool here. Large trials found that low-dose colchicine reduced major cardiovascular events by roughly a third in patients with stable coronary disease and by about a quarter in patients recovering from a heart attack.¹⁰ Imaging studies have shown how colchicine achieves part of this benefit: it shrank the soft, low-density portions of plaque by about 40 percent over a year, compared to roughly 17 percent in patients on standard therapy alone, with the plaque reduction correlating directly to drops in inflammation markers.¹¹ In other words, colchicine does not just reduce inflammation in the blood; it appears to remodel the plaques themselves into safer configurations.

Blood Flow Patterns and Plaque Location

If you have ever wondered why plaque tends to form in specific spots rather than uniformly coating every artery, the answer lies in blood flow. Arteries are not passive pipes; the shear force that flowing blood exerts on the vessel wall profoundly affects plaque behavior. Regions of the artery exposed to low shear stress, typically at bends and branch points where blood flow slows and becomes turbulent, are far more likely to develop dangerous plaques with thin caps and large fatty cores.¹²

Follow-up studies have tracked this over time. Regions of low shear stress show progressive plaque thickening, while regions exposed to normal blood flow remain essentially unchanged.¹³ This local mechanical environment also influences whether therapeutic plaque regression succeeds: areas with low shear stress showed significantly more plaque buildup compared to high-shear areas, even in patients receiving treatment.¹⁴ This is a humbling reminder that drugs cannot completely override physics. Exercise, which increases blood flow and therefore shear stress, may have some beneficial effects on plaque composition and collateral blood supply, though isolating exercise’s independent contribution to plaque regression from its effects on cholesterol and inflammation is difficult.

Diet and Lifestyle Changes

The idea that diet alone can reverse heart disease gained attention from small studies using very low-fat, plant-based diets. Some researchers have reported evidence that coronary artery disease may be reversed with diets containing customary levels of plant-sourced fat that are low in saturated fat.¹⁵ The evidence here is real but limited. The most cited lifestyle-reversal studies enrolled small numbers of highly motivated participants who changed their diets dramatically and often added exercise, stress management, and social support at the same time. It is hard to say which component drove the results, and adherence to strict plant-based diets over decades is rare in the general population.

That said, dietary patterns clearly affect the underlying drivers of plaque. Diets high in fiber, unsaturated fats, and vegetables lower LDL cholesterol, reduce inflammation, and improve the health of the artery lining. These effects are more modest than what drugs achieve, but they stack on top of pharmacotherapy. Weight loss, quitting smoking, and regular aerobic exercise each independently improve the metabolic environment that feeds plaque growth. For someone already taking a statin and eating a reasonably healthy diet, the marginal benefit of switching to a strict plant-based regimen is less clear than the marginal benefit of adding ezetimibe or colchicine.

The Gut Microbiome Connection

Your gut bacteria influence plaque in ways that researchers are still mapping. The most studied pathway involves trimethylamine N-oxide, or TMAO, a compound produced when gut bacteria digest certain nutrients found in red meat, eggs, and full-fat dairy. TMAO promotes atherosclerosis through several mechanisms, including damage to the artery lining, activation of platelets, and promotion of the clotting process.¹⁶ People with higher TMAO levels have a higher risk of heart attacks and strokes.

The flip side is also interesting: certain gut-produced metabolites appear to protect against plaque. Indole-3-propionic acid, made by bacteria that ferment tryptophan (an amino acid abundant in many plant and animal proteins), promotes reverse cholesterol transport, helping to pull cholesterol out of foam cells and send it to the liver. When levels of this metabolite drop, plaque progression accelerates.⁴ These findings suggest that the composition of your gut microbiome, shaped by what you eat, may tilt the balance toward or away from plaque regression, though no one has yet turned this into a reliable clinical intervention.

Supplements With Preliminary Evidence

A few supplements have generated genuine scientific interest, though none has the strength of evidence behind statins or PCSK9 inhibitors.

Nattokinase

Nattokinase is an enzyme derived from natto, a traditional Japanese fermented soybean food. A large clinical study with over 1,000 participants found that after 12 months of nattokinase consumption, carotid artery plaque shrank significantly, with the average size decreasing by up to 36 percent alongside reductions in the thickness of the artery wall.¹⁷ Other reviews have confirmed that nattokinase improves lipid profiles and reduces plaque area with a favorable safety profile.¹⁸ These results are promising, but the strongest studies come from East Asian populations with dietary and genetic backgrounds that may not generalize worldwide. The study designs have also generally lacked the blinded, placebo-controlled rigor of major statin trials. Nattokinase is worth watching, but it is not a substitute for proven medications in people with established heart disease.

Vitamin K2

Vitamin K2 activates a protein called matrix Gla protein, which inhibits calcium from depositing in soft tissues like artery walls.¹⁹ Deficiency of vitamin K2 has been linked to arterial calcification, particularly in patients with chronic kidney disease, who are especially prone to vascular calcium buildup.²⁰ This has led to widespread supplement marketing, but the observational evidence linking low vitamin K to calcification does not prove that taking supplements will reverse calcification that has already occurred. Clinical trials on this question are still underway, and the honest assessment right now is that vitamin K2 may help prevent arterial calcification in people who are deficient but has not been shown to dissolve existing calcified plaque.

Chelation Therapy

Chelation therapy uses intravenous EDTA, a chemical that binds metals like calcium and iron and carries them out of the body. Proponents argue this pulls calcium from arterial plaque, weakening the deposits. The evidence is mixed and the scientific community remains divided. A Cochrane systematic review found no clear difference in death rates, heart attacks, or angina between chelation therapy and placebo in patients with coronary artery disease.²¹

However, one large trial did find that chelation reduced cardiovascular events by about 18 percent overall, with a particularly strong effect in patients with diabetes, who saw a 41 percent reduction.²² A broader systematic review of 24 studies noted that most reported some improvement in outcomes following EDTA treatment, with the largest benefits in patients with diabetes and severe peripheral artery disease.²³ The problem is that study quality varies widely, and different trials used different dosing regimens, making it hard to draw firm conclusions. Chelation therapy is not recommended in mainstream cardiology guidelines, but the signal in diabetic patients is strong enough that replication trials have been called for.

Plaque Starts Earlier Than You Think

Fatty streaks, the precursors to full-blown plaques, have been found in the arteries of children and young adults. These early lesions are clinically harmless and potentially reversible, but if risk factors like high cholesterol, high blood pressure, or smoking are present early in life, they can progress to fibrous plaques and eventually to the calcified, complex lesions seen in heart disease patients.²⁴ This has implications for prevention: the earlier you address cardiovascular risk factors, the more likely the body can clear early deposits before they harden into something much more difficult to reverse. By the time a middle-aged adult has calcified coronary plaque, no currently available therapy can return the artery to its teenage state. What treatment can do is stabilize and modestly shrink the plaque while preventing new deposits.

RNA Therapies and Nanomedicine on the Horizon

The next generation of plaque-fighting tools is already in clinical trials. One exciting area targets lipoprotein(a), a genetically determined particle that raises cardiovascular risk independently of LDL cholesterol. Unlike LDL, lipoprotein(a) levels barely budge with statins or lifestyle changes. New RNA-based drugs, including pelacarsen, olpasiran, and lepodisiran, directly reduce the liver’s production of lipoprotein(a) and are being tested in large cardiovascular outcomes trials.²⁵ If these pan out, they could close a significant gap in plaque prevention for people whose risk comes largely from this stubborn particle.

Nanotechnology represents a more futuristic approach. Researchers are designing nanoparticles that can carry drugs directly to atherosclerotic plaques, concentrating anti-inflammatory or lipid-lowering agents exactly where they are needed while sparing the rest of the body from side effects.²⁶ These platforms use materials ranging from gold and iron oxide particles to liposomes and polymer-based carriers, and some incorporate imaging agents so doctors can simultaneously treat and visualize a plaque.²⁷ None of this is available outside research settings yet, but targeted delivery could eventually make plaque regression more efficient and less dependent on the body’s own slow cholesterol-clearing machinery.

What Actually Works, Ranked by Evidence Strength

If you’re trying to figure out what is worth your attention and what is hype, here is a rough hierarchy based on the current evidence:

Strong evidence for plaque regression: High-intensity statins, statins combined with ezetimibe, statins combined with PCSK9 inhibitors. These have been demonstrated in multiple trials using direct imaging of coronary plaques.
Strong evidence for plaque stabilization and event reduction: Low-dose colchicine, added to standard therapy. Imaging and outcomes data both support its use.
Moderate evidence: Plant-based and low-saturated-fat diets, regular aerobic exercise, nattokinase supplementation. Plausible mechanisms and some clinical data, but trial designs are less rigorous or the populations studied are narrower.
Preliminary or conflicting evidence: Vitamin K2 supplementation, chelation therapy. Biological rationale exists, and some positive signals have been reported, but the evidence does not yet justify routine use outside of research settings.
Still in development: RNA therapies for lipoprotein(a), nanoparticle-based targeted delivery. Promising but not yet available for clinical use.

Nothing currently available erases arterial plaque entirely. But the combination of aggressive lipid lowering, anti-inflammatory treatment, and sensible lifestyle choices can meaningfully shrink plaques, transform their composition from fragile to stable, and reduce the risk that they will cause a heart attack or stroke. For most people with established coronary disease, the practical answer is a well-chosen statin, possibly with one or two add-on medications, and the dietary and exercise habits that support the drugs’ effects.